Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

A high-throughput screen of pharmacologically active compounds for inhibitors of UHRF1 reveals epigenetic activity of anthracycline derivative chemotherapeutic drugs.

Giovinazzo H, Walker D, Wyhs N, Liu J, Esopi DM, Vaghasia AM, Jain Y, Bhamidipati A, Zhou J, Nelson WG, Yegnasubramanian S.

Oncotarget. 2019 Apr 30;10(32):3040-3050. doi: 10.18632/oncotarget.26889. eCollection 2019 Apr 30.

2.

CD38 is methylated in prostate cancer and regulates extracellular NAD.

Mottahedeh J, Haffner MC, Grogan TR, Hashimoto T, Crowell PD, Beltran H, Sboner A, Bareja R, Esopi D, Isaacs WB, Yegnasubramanian S, Rettig MB, Elashoff DA, Platz EA, De Marzo AM, Teitell MA, Goldstein AS.

Cancer Metab. 2018 Sep 21;6:13. doi: 10.1186/s40170-018-0186-3. eCollection 2018.

3.

ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner.

Brosnan-Cashman JA, Yuan M, Graham MK, Rizzo AJ, Myers KM, Davis C, Zhang R, Esopi DM, Raabe EH, Eberhart CG, Heaphy CM, Meeker AK.

PLoS One. 2018 Sep 18;13(9):e0204159. doi: 10.1371/journal.pone.0204159. eCollection 2018.

4.

Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate.

Markowski MC, Hubbard GK, Hicks JL, Zheng Q, King A, Esopi D, Rege A, Yegnasubramanian S, Bieberich CJ, De Marzo AM.

Prostate. 2018 Sep;78(13):992-1000. doi: 10.1002/pros.23657. Epub 2018 May 30.

PMID:
29851094
5.

Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.

Haffner MC, Guner G, Taheri D, Netto GJ, Palsgrove DN, Zheng Q, Guedes LB, Kim K, Tsai H, Esopi DM, Lotan TL, Sharma R, Meeker AK, Chinnaiyan AM, Nelson WG, Yegnasubramanian S, Luo J, Mehra R, Antonarakis ES, Drake CG, De Marzo AM.

Am J Pathol. 2018 Jun;188(6):1478-1485. doi: 10.1016/j.ajpath.2018.02.014. Epub 2018 Mar 22.

6.

A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease.

Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, Liu Y, Kozlitina J, Stender S, Wood GC, Stepanchick AN, Still MD, McCarthy S, O'Dushlaine C, Packer JS, Balasubramanian S, Gosalia N, Esopi D, Kim SY, Mukherjee S, Lopez AE, Fuller ED, Penn J, Chu X, Luo JZ, Mirshahi UL, Carey DJ, Still CD, Feldman MD, Small A, Damrauer SM, Rader DJ, Zambrowicz B, Olson W, Murphy AJ, Borecki IB, Shuldiner AR, Reid JG, Overton JD, Yancopoulos GD, Hobbs HH, Cohen JC, Gottesman O, Teslovich TM, Baras A, Mirshahi T, Gromada J, Dewey FE.

N Engl J Med. 2018 Mar 22;378(12):1096-1106. doi: 10.1056/NEJMoa1712191.

7.

MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer.

Baena-Del Valle JA, Zheng Q, Esopi DM, Rubenstein M, Hubbard GK, Moncaliano MC, Hruszkewycz A, Vaghasia A, Yegnasubramanian S, Wheelan SJ, Meeker AK, Heaphy CM, Graham MK, De Marzo AM.

J Pathol. 2018 Jan;244(1):11-24. doi: 10.1002/path.4980. Epub 2017 Nov 14.

8.

Molecular phylogeny and systematics of native North American lumbricid earthworms (Clitellata: Megadrili).

Csuzdi C, Chang CH, Pavlícek T, Szederjesi T, Esopi D, Szlávecz K.

PLoS One. 2017 Aug 9;12(8):e0181504. doi: 10.1371/journal.pone.0181504. eCollection 2017.

9.

AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic dissemination.

Haffner MC, Esopi DM, Chaux A, Gürel M, Ghosh S, Vaghasia AM, Tsai H, Kim K, Castagna N, Lam H, Hicks J, Wyhs N, Biswal Shinohara D, Hurley PJ, Simons BW, Schaeffer EM, Lotan TL, Isaacs WB, Netto GJ, De Marzo AM, Nelson WG, An SS, Yegnasubramanian S.

Nat Commun. 2017 Jul 26;8(1):142. doi: 10.1038/s41467-017-00084-8.

10.

Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay.

Ajiboye AS, Esopi D, Yegnasubramanian S, Denmeade SR.

Prostate. 2017 Jun;77(8):829-837. doi: 10.1002/pros.23323. Epub 2017 Feb 22.

11.

Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.

Haffner MC, Weier C, Xu MM, Vaghasia A, Gürel B, Gümüşkaya B, Esopi DM, Fedor H, Tan HL, Kulac I, Hicks J, Isaacs WB, Lotan TL, Nelson WG, Yegnasubramanian S, De Marzo AM.

J Pathol. 2016 Jan;238(1):31-41. doi: 10.1002/path.4628. Epub 2015 Oct 14.

12.

Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.

Hurley PJ, Hughes RM, Simons BW, Huang J, Miller RM, Shinder B, Haffner MC, Esopi D, Kimura Y, Jabbari J, Ross AE, Erho N, Vergara IA, Faraj SF, Davicioni E, Netto GJ, Yegnasubramanian S, An SS, Schaeffer EM.

Cancer Res. 2015 Oct 15;75(20):4322-34. doi: 10.1158/0008-5472.CAN-15-0024. Epub 2015 Aug 20.

13.

A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells.

Yu SH, Zheng Q, Esopi D, Macgregor-Das A, Luo J, Antonarakis ES, Drake CG, Vessella R, Morrissey C, De Marzo AM, Sfanos KS.

Cancer Immunol Res. 2015 Oct;3(10):1175-84. doi: 10.1158/2326-6066.CIR-15-0013. Epub 2015 Jun 5.

14.

Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas.

Tan HL, Haffner MC, Esopi DM, Vaghasia AM, Giannico GA, Ross HM, Ghosh S, Hicks JL, Zheng Q, Sangoi AR, Yegnasubramanian S, Osunkoya AO, De Marzo AM, Epstein JI, Lotan TL.

Mod Pathol. 2015 Mar;28(3):446-56. doi: 10.1038/modpathol.2014.115. Epub 2014 Sep 12.

15.

Tracking the clonal origin of lethal prostate cancer.

Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gürel M, Hicks J, Meeker AK, Halushka MK, Simons JW, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S.

J Clin Invest. 2013 Nov;123(11):4918-22. doi: 10.1172/JCI70354. Epub 2013 Oct 25.

16.

Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations.

Gerber JM, Gucwa JL, Esopi D, Gurel M, Haffner MC, Vala M, Nelson WG, Jones RJ, Yegnasubramanian S.

Oncotarget. 2013 May;4(5):715-28.

17.

Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer.

Weier C, Haffner MC, Mosbruger T, Esopi DM, Hicks J, Zheng Q, Fedor H, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S.

J Pathol. 2013 Jun;230(2):174-83. doi: 10.1002/path.4186.

18.

DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases.

Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, Luo J, Xu J, Isaacs WB, Bova GS, Yegnasubramanian S.

Sci Transl Med. 2013 Jan 23;5(169):169ra10. doi: 10.1126/scitranslmed.3005211.

19.

A novel source for miR-21 expression through the alternative polyadenylation of VMP1 gene transcripts.

Ribas J, Ni X, Castanares M, Liu MM, Esopi D, Yegnasubramanian S, Rodriguez R, Mendell JT, Lupold SE.

Nucleic Acids Res. 2012 Aug;40(14):6821-33. doi: 10.1093/nar/gks308. Epub 2012 Apr 13.

20.

Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers.

Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C, Nelson WG, Netto GJ, De Marzo AM, Yegnasubramanian S.

Oncotarget. 2011 Aug;2(8):627-37.

21.

PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.

Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De Marzo AM.

Clin Cancer Res. 2011 Oct 15;17(20):6563-73. doi: 10.1158/1078-0432.CCR-11-1244. Epub 2011 Aug 30.

22.

Identification of replication competent murine gammaretroviruses in commonly used prostate cancer cell lines.

Sfanos KS, Aloia AL, Hicks JL, Esopi DM, Steranka JP, Shao W, Sanchez-Martinez S, Yegnasubramanian S, Burns KH, Rein A, De Marzo AM.

PLoS One. 2011;6(6):e20874. doi: 10.1371/journal.pone.0020874. Epub 2011 Jun 17.

23.

Chromosome-wide mapping of DNA methylation patterns in normal and malignant prostate cells reveals pervasive methylation of gene-associated and conserved intergenic sequences.

Yegnasubramanian S, Wu Z, Haffner MC, Esopi D, Aryee MJ, Badrinath R, He TL, Morgan JD, Carvalho B, Zheng Q, De Marzo AM, Irizarry RA, Nelson WG.

BMC Genomics. 2011 Jun 13;12:313. doi: 10.1186/1471-2164-12-313.

24.

Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.

Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, Netto G, De Marzo AM, Nelson WG, Yegnasubramanian S.

Nat Genet. 2010 Aug;42(8):668-75. doi: 10.1038/ng.613. Epub 2010 Jul 4.

25.

Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth.

Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M, Wu H, Bova SG, Biswal S.

Mol Cancer Ther. 2010 Feb;9(2):336-46. doi: 10.1158/1535-7163.MCT-09-0589. Epub 2010 Feb 2.

Supplemental Content

Support Center